Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.

CRP levels decreased significantly in both groups, though the magnitude of reduction was substantially greater in the atorvastatin group ( p < 0.001), resulting in a highly significant between-group difference at 6 months ( p < 0.001).

also in 132,142 other papers